Heptares

84 articles with Heptares

• Heptares Highlights Potential Of Star® Proteins As Antigens For GPCR-Targeted Antibody Discovery In New Scientific Publication

  12/16/2013

• Heptares to Present at Upcoming Scientific and Biotech Industry Conferences

  10/31/2013

• Heptares Delivers First Stabilised GPCR (StaR®) to MorphoSys AG for Antibody Discovery

  10/10/2013

• Heptares to Present at Upcoming Scientific and Biotech Industry Conferences

  9/6/2013

• Heptares Achieves First Research Milestone in Research Collaboration With Cubist Pharmaceuticals, Inc.

  7/22/2013

• Heptares Announces Publication in Nature of Class B GPCR Structure

  7/17/2013

• Heptares Gains $21 Million to Fund Alzheimer's Treatment

  6/27/2013

• Heptares to Present at Upcoming Biotech Industry Conferences

  6/6/2013

• Heptares Achieves All Research Milestones and Receives Milestone Payment From GPCR Drug Discovery Agreement With Takeda Pharmaceutical Co. Ltd.

  4/29/2013

• Heptares to Present at Upcoming Scientific and Biotech Industry Conferences

  4/16/2013

• Heptares to Present at Boston Biotech BD and Future Leaders in the Biotech Industry Conferences

  4/3/2013

• Heptares Stars&#0174 Enable "Reverse Pharmacology" Approach to Accelerate GPCR-Focused Drug Discovery

  3/18/2013

• MorphoSys AG and Heptares Sign Alliance to Develop Antibody Therapeutics Targeting GPCRs

  2/13/2013

• Heptares and UK Medical Research Council (MRC) Extend GPCR Collaboration

  6/19/2012

• Heptares Review Article Highlights Promise of Structure-Based Drug Design for G Protein Coupled Receptors (GPCRs)

  4/25/2012

• Heptares Grants Shire plc an Exclusive Worldwide $190 Million License to Develop and Commercialise Novel Drug Candidate for CNS Disorders

  3/20/2012

• Heptares to Present at 6th Annual BIO-Europe Spring Conference on 20 March 2012

  3/15/2012

• Oxygen Healthcare Ltd. (O2h) Announces Expanded Chemistry Collaboration With Heptares

  7/14/2011

• AstraZeneca PLC, Heptares In Study Pact Targeting GPCR Drugs; Heptares to Receive $6.25 Million Upfront

  5/31/2011

• Heptares and Takeda Pharmaceutical Co. Ltd. Initiate Drug Discovery Collaboration Focused on GPCR Linked to CNS Disorders; Heptares to Get GBP 4.5 Million Upfront and Up to GBP 60.5 Million

  4/11/2011